Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors

Although the clinical efficacies of third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as osimertinib in the treatment of non-small cell lung cancer (NSCLC) with EGFR-activating mutations are promising, drug-acquired resistance inevitably occurs whether t...

Descripción completa

Detalles Bibliográficos
Autor principal: Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442612/
https://www.ncbi.nlm.nih.gov/pubmed/37609474
http://dx.doi.org/10.1016/j.pccm.2022.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442612/
https://www.ncbi.nlm.nih.gov/pubmed/37609474
http://dx.doi.org/10.1016/j.pccm.2022.10.001

Ejemplares similares